CERo Therapeutics Announces Dose Intensification in Phase 1 Study of CER-1236 in Acute Myeloid Leukemia

Study investigator of Phase 1 trial presented poster at Society of Hematologic Oncology 13^th annual conference highlighting original study protocol

SOUTH SAN FRANSCISCO, Calif., Sept. 08, 2025 (GLOBE NEWSWIRE) -- CERo Therapeutics Holdings, Inc., (Nasdaq: CERO) (“CERo” or the “Company”) an innovative cellular immunotherapy company seeking to advance the next generation of engineered T cell therapeutics that employ phagocytic mechanisms, announces it has administered a second dose in the second patient in the first cohort of its Phase 1 CER-1236 clinical trial focused on patients with acute myeloid leukemia (AML).  The multi-dose intensification has been authorized by the study’s Institutional Review Board (IRB) following review of initial pharmacokinetic data from the first two enrolled patients showing cell expansion and will effectively double the amount of cell product infused in each subject relative to the previous protocol approach. 

Read more at globenewswire.com